Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
ID: 349976Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349976

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-027.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access" (X01), aimed at providing researchers access to critical biospecimens and related data from the PATH Study. This initiative seeks to support studies that align with the objectives of tobacco regulatory science, emphasizing the importance of understanding tobacco use behaviors and health outcomes in the U.S. The PATH Study, which has been collecting longitudinal data since 2011, includes biological samples such as urine, serum, plasma, and genomic DNA. Applications will be accepted starting March 30, 2024, with a final submission deadline of October 31, 2026. Interested applicants can find more information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-027-Full-Announcement.html
    PAR-24-027.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA), has announced the funding opportunity titled "Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access" (X01). This initiative allows researchers to access critical biospecimens and related data gathered from the PATH Study, aimed at understanding tobacco use and its health outcomes in the U.S. Initially launched in 2011, the PATH Study collects longitudinal data from a national cohort, which includes biological samples such as urine, serum, plasma, and genomic DNA. The NOFO emphasizes the significance of meritorious studies aligned with PATH objectives in tobacco regulatory science. Applicants must confirm the availability of necessary biospecimens before applying and adhere to detailed application instructions. The funding announcement includes various eligibility requirements for institutions, emphasizing the importance of diversity among applicants. The review process will focus on the scientific merit of proposals, with an expected outcome of advancing public health knowledge and policies regarding tobacco use. The applications will be accepted starting March 30, 2024, with a final due date of October 31, 2026, and there is no direct funding associated with this award mechanism.
    Similar Opportunities
    NIH Brain Development Cohorts (NBDC) Biospecimen Access (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for access to biospecimens from the Adolescent Brain Cognitive Development (ABCD) Study, the largest longitudinal study of child health in the United States. This initiative, titled NIH Brain Development Cohorts (NBDC) Biospecimen Access, allows researchers to utilize biological samples such as blood, saliva, and hair to investigate the effects of environmental and biological factors on adolescent brain development and health. The program does not provide direct funding for research costs; applicants must secure their own funding and can apply for specific samples to enhance scientific understanding of adolescent health over a maximum project period of three years. Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by May 5, 2026.
    Tobacco Regulatory Science (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Tobacco Regulatory Science (R01 Clinical Trial Optional)" funding opportunity, aimed at supporting biomedical and behavioral research to inform the regulation of tobacco products and protect public health. This initiative seeks R01 research project grant applications that address key research priorities, including the composition and design of tobacco products, toxicity assessments, addiction studies, and the health effects of tobacco use. A total of up to six R01 grants, with a combined funding of $4 million for fiscal year 2024, will be awarded to eligible applicants, which include a diverse range of institutions and organizations. Interested parties should submit their applications by May 4, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-23-017.html for further details.
    Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00), aimed at fostering a new generation of independent researchers in the field of tobacco regulation. This grant program is designed to support postdoctoral researchers transitioning to independent faculty positions, with a focus on research that informs the regulation of tobacco products as mandated by the Family Smoking Prevention and Tobacco Control Act. The K99 phase provides up to two years of mentored research training, followed by the R00 phase, which offers up to three years of independent research support, targeting areas such as tobacco product composition, health effects, addiction, and the evaluation of FDA regulatory actions. Applications are due periodically, with the next deadlines on November 14, 2023, and March 12, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "NIDDK Central Repository Non-renewable Sample Access," aimed at facilitating access to valuable biological samples for research in health-related fields, particularly diabetes, kidney, and digestive diseases. Eligible applicants, including various educational institutions and organizations, can apply for access to non-renewable samples and associated data from significant clinical studies, with the requirement to submit a report from the NIDDK Central Repository documenting sample availability. This initiative promotes equitable distribution of samples and collaboration among researchers to enhance research outcomes, with no funds awarded; instead, access approvals are based on the scientific merit of applications and sample availability. Interested parties should note that the application deadline is June 26, 2025, and are encouraged to engage with the Repository at least six weeks prior to submission for an assessment. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required )
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Pathway to Independence Award in Tobacco Regulatory Research (K99/R00), aimed at fostering a new generation of independent researchers focused on tobacco regulation under the FDA's jurisdiction. This grant supports postdoctoral researchers in transitioning to independent faculty positions through a two-phase program: the K99 phase provides up to two years of mentored training, while the R00 phase offers up to three years of independent research funding, with a total funding commitment of $750,000 for approximately five awards. Eligible applicants must have no more than four years of postdoctoral experience and are encouraged to align their proposals with FDA scientific domains, addressing critical issues such as product composition, health effects, and marketing influences. Interested candidates should submit their applications by March 12, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Pulmonary Outcomes and Sequelae after Treatment-TB (POST-TB)," aimed at supporting research on the long-term cardiopulmonary effects following tuberculosis (TB) treatment in both adults and children, particularly focusing on individuals with and without HIV. This initiative encourages innovative epidemiological and observational studies to better characterize post-TB lung disease (PTLD) and its associated health impacts, utilizing existing cohorts of TB participants. Interested applicants, including higher education institutions, non-profits, and government entities, must adhere to specific guidelines for submission through the NIH ASSIST system, with applications accepted until May 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research," aimed at advancing cancer research through the use of the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications that leverage high-quality, pre-diagnostic biospecimens and associated data to explore cancer risk factors and develop early detection biomarkers, emphasizing the unique characteristics of the PLCO resources. Eligible applicants include a diverse range of institutions, including historically black colleges, tribal colleges, and various community organizations, with no cost-sharing requirement. The application deadline is October 11, 2024, and interested parties can find more information and contact details at the NIH website or via email at OERWebmaster03@od.nih.gov.
    Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)" aimed at innovative analyses of existing datasets related to substance use behaviors and disorders. This initiative seeks to enhance understanding of the etiology and epidemiology of drug use, prevention strategies, and health service utilization by leveraging already available social science, neuroimaging, and administrative data, excluding primary data collection. The funding, with an anticipated commitment of $2 million for 3-5 awards, emphasizes compliance with ethical research practices and is open to a wide range of eligible applicants, including educational institutions and nonprofit organizations. Applications are due by November 15, 2024, and further details can be found at the provided link or by contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDCR Prospective Observational or Biomarker Validation Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Institute of Dental and Craniofacial Research (NIDCR) for investigator-initiated observational studies or biomarker validation studies that require prospective data collection. This cooperative agreement aims to support research that enhances oral health by generating robust clinical data and validating biomarkers with established preliminary data. The funding is available for projects up to five years, contingent upon NIH appropriations, and emphasizes the significance of the proposed research and the investigator's capability. Interested applicants can find more information and application guidelines at the provided link, with the application due date set for May 7, 2026, and inquiries directed to grantsinfo@nih.gov.